Antimicrobial Wound Gel for Surgical Site Complications

Palo Alto (17 mi)

Overseen byGiles Scuderi

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: N/A

Waitlist Available

Sponsor: Northwell Health

No Placebo Group

Trial Summary

What is the purpose of this trial?This is a single-site, prospective, clinical study of subjects that are scheduled to undergo either total hip or total knee arthroplasties. It is anticipated that surgical wounds treated with SurgX will exhibit reduced surgical site complication rates and improved post-operative treatment outcomes by potentially decreasing site bioburden of both free-floating and biofilm-entrenched organisms.

Eligibility Criteria

This trial is for adults over 18 who are scheduled for primary hip or knee replacement surgery and can consent to participate. They must be able to follow the study's procedures throughout its duration. People with allergies to any study products, mental impairments preventing proper consent, or those considered vulnerable under specific federal regulations cannot join.

Treatment Details

The trial is testing SurgX Antimicrobial Wound Gel against standard wound care in patients undergoing hip or knee replacements. The goal is to see if SurgX reduces complications and improves outcomes by targeting bacteria at the surgical site.

2Treatment groups

Experimental Treatment

Group I: Treatment GroupExperimental Treatment1 Intervention

The treatment group will receive SurgX™ Antimicrobial Wound Gel™ applied over incision after closure and then re-applied at first dressing change on day of discharge in addition to standard of care.

Group II: Control GroupExperimental Treatment1 Intervention

The control group will receive standard of care.